Connect with us

News

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks

gbafNews28

Appili Therapeutics Inc. (TSXV: APLI) (the Company or Appili), a biopharmaceutical company focused on anti-infective drug development, today announced that Health Canada provided regulatory clearance for Appilis Phase 2 study evaluating FUJIFILM Toyama Chemicals (FFTC) favipiravir as a preventative measure against COVID-19 outbreaks. Dr. Allison McGeer, senior clinician scientist at Sinai Healths Lunenfeld-Tanenbaum Research Institute in Toronto, Ontario is the studys primary investigator. Appili expects trial recruitment to begin imminently. Researchers will enroll approximately 760 subjects, both residents and staff, at 16 long-term care homes (LTCHs) in Ontario. The National Institute on Ageing has estimated that as of May 6, 2020, 82 percent of deaths related to COVID-19 in Canada were associated with long-term care facilities.i

Given the severity of COVID-19 amongst the elderly, and the evidence of ongoing transmission with severe outcomes in LTCHs, it is critical to develop interventions that minimize the spread of disease in this setting. As vaccines and treatment for COVID-19 remain unavailable, we must explore all possible solutions, said Dr. McGeer. We look forward to working with Appili on this study, as the pandemic continues to present devastating consequences for LTCH residents and their families.

The Trial

The partially blinded, cluster randomized placebo-controlled trial (cluster-RCT) will recruit approximately 760 participants across 16 LTCHs in Ontario. Investigators from the University of Toronto, Sunnybrook Health Sciences Centre, and Unity Health Toronto are also participating in the study. The primary objective of the Phase 2 trial is to evaluate the efficacy of favipiravir or 25 days compared with placebo as a prophylaxis to prevent COVID-19 outbreaks in LTCHs. The primary endpoint will be outbreak control, defined as no new cases of COVID-19 in residents for 24 consecutive days up to Day 40 after the start of prophylaxis. Secondary objectives include measures of safety, rates of infection, disease progression, and fatality rates.

With the strikingly high fatality rate from COVID-19 in long-term care facilities, there is a particularly urgent need to protect our most vulnerable members of society. Preventing and controlling COVID-19 outbreaks in long-term care facilities is therefore of extreme importance, said Yoav Golan, MD, Chief Medical Officer at Appili Therapeutics. Industry and academia are coming together in unprecedented ways to mitigate this crisis, and Appili is proud to be part of this unique collaboration. Dr. McGeer and her team at Mount Sinai, along with our other medical partners from some of the premier institutions in Toronto, have extensive experience in working to mitigate respiratory infections in long-term care settings. Together with the support from FFTC, we are in a unique position to evaluate the utility of favipiravir as a COVID-19 prophylaxis to control further outbreaks in these facilities, which could be a significant advance for Canadian patients, with implications for global application in similar high-risk outbreak settings.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

Favipiravir

Favipiravir is a broad-spectrum antiviral approved in Japan under the brand name Avigan. Japanese health authorities provided approval to FFTC in 2014 to use Avigan as a treatment and stockpile countermeasure for pandemic influenza outbreak. Recent studies suggest favipiravir may have potential utility for the treatment of COVID-19.iiiii Researchers in Wuhan, China, reported in early February that favipiravir demonstrated anti-viral activity in vitro against SARS-CoV-2. Small-scale clinical trials conducted in China have also indicated that favipiravir may provide clinical benefit in patients with COVID-19.

About Appili Therapeutics

Appili Therapeutics Inc. was founded to advance the global fight against infectious disease by matching clearly defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this critical disease space. Appili has built a pipeline of assets designed to address a broad range of significant unmet medical needs in the infectious disease landscape. This diverse pipeline aims to address some of the most urgent threats in global public health, including ATI-2307, a novel, broad spectrum, clinical-stage antifungal candidate in development for severe and difficult-to-treat invasive fungal infections; ATI-1701, a vaccine candidate for tularemia, a very serious biological weapons threat; ATI-1503, a drug discovery program aimed at generating a novel class of antibiotics with broad-spectrum activity against Gram-negative superbugs; and ATI-1501, which employs Appilis proprietary, taste-masked, oral-suspension technology with metronidazole for the growing number of patients with difficulty swallowing. Headquartered in Halifax, Nova Scotia, with offices in Toronto, Ontario, Appili is pursuing worldwide opportunities in collaboration with scientific and industry commercial partners, governments, and government agencies. For more information, visit www.AppiliTherapeutics.com.

Forward looking statements

This news release contains forward-looking statements, which reflect the current expectations of the Companys management for future growth, results of operations, performance and business prospects and opportunities, including statements with respect to: the scope and parameters of the proposed clinical trial and the likelihood that the clinical trial will be consummated on the terms and timeline provided herein or at all; and the potential use of favipiravir as a prophylactic agent for the treatment of COVID-19. Wherever possible, words such as may, would, could, should, will, anticipate, believe, plan, expect, intend, estimate, potential for and similar expressions have been used to identify these forward-looking statements. Forward looking statements contained in this press release are provided in reliance on certain assumptions, including with respect to: securing all requisite required approvals and funding for the clinical trial; finalizing a mutually acceptable clinical trial agreement and related agreements with the applicable clinical research organizations relating to this clinical trial; patient enrolment; and other expectations and assumptions concerning the proposed clinical trial (including with respect to potential outcomes and benefits). Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, the Company cannot give assurance that these expectations will prove to have been correct.

Forward-looking statements involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, economic, competitive, political and social uncertainties; known and unknown risks and liabilities relating to the ongoing COVID-19 pandemic; risks relating to the inability of Appili to secure any requisite rights to manufacture and commercialize favipiravir in Canada on favourable terms or at all; unforeseen events, developments, or factors causing any of the aforesaid expectations and assumptions not to be correct; and the other risk factors listed in the annual information form of the Company dated July 3, 2019 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.


i MacCharles, Tonda. 82% of Canadas COVID-19 deaths have been in long-term care, new data reveals. The Star Accessed online May 7, 2020.

ii Cai et al (2020) Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. https://doi.org/10.1016/j.eng.2020.03.007

iii Chen et al (2020) Favipiravir versus arbidol for COVID-19: A Randomized Clinical Trial. medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037432

Media Relations Contact:

Canadian Media:

Chantal Allan

Sam Brown Inc.

T: 613-319-4384 (CAN)

T: 805-242-3080 (U.S.)

E: [email protected]

US/Trade Media:

Andrea Cohen

Sam Brown Inc.

T: 917-209-7163

E: [email protected]

Investor Relations Contact:

Kimberly Stephens, CFO

Appili Therapeutics Inc.

TSXV: APLI

E: [email protected]

News

DHL sends healthcare supplies for World Health Organization to the Pacific Islands

gbafNews28

  • Tourism-dependent islands badly impacted by more than 90% decline in passenger flights
  • Supplementary COVID-19 supplies moved through Singapore and Fiji to reach the Pacific islands

SINGAPORE – Media OutReach – 26 November 2020 – The far flung islands in the Pacific have not been spared the brunt of COVID-19. The World Health Organization has been working tirelessly to ensure much-needed supplies and healthcare equipment reach the shores of these islands. While the number of cases has been relatively small, many of these countries, which are heavily dependent on tourism, have been impacted by the dramatic cuts in passenger flights, resulting in a logistical challenge to send in basic supplies on a regular basis.

[View Image]

Image taken prior to Covid-19

 

This week, the World Health Organization coordinated its latest cargo donation through DHL Global Forwarding (“DHL”), the freight specialist of Deutsche Post DHL Group, to support the islands’ fight against COVID-19. The shipments, worth over EUR 650,000 contained medical devices such as oxygen concentrator sets, patient monitors and pulse oximeters, were airfreighted from Singapore to Fiji, where they will be dispatched to eight islands in the Pacific. The Pacific Islands, which had previously managed to avoid large outbreaks, experienced a recent spike in COVID-19 infections that doubled its total number of cases.

 

Due to the shortage of air capacity with passenger flights reduced by more than 90%, the freight had to be broken down into three tranches, sent some two weeks apart. DHL Global Forwarding organized the first shipment from Singapore to Fiji on 22 October, and will be stored till the last shipment arrives on 19 November. From Fiji, special flights or shipping lines were then organized into eight markets, Cook Islands, Kiribati, Nauru, Niue, Solomon Islands, Tokelau, Tuvalu and Tonga, to ensure they reached their destination.

 

“Ensuring that the Pacific Island countries have access to the necessary medical equipment and supplies to prepare for and respond to COVID-19 is a priority for the World Health Organization. But reaching such remote places, especially when so many airports are closed, is a huge logistical challenge. WHO is happy to be working with our partners like DHL to be able to make this happen.” said Dr Takeshi Kasai, WHO Regional Director for the Western Pacific.

 

The medical devices, which will be sent to hospitals and other healthcare institutions, will aid local medical professionals in treating COVID-19 patients.

 

“Whilst the Pacific Islands’ geographic distance from densely populated countries had helped them avert major outbreaks during the pandemic, it has equally worked against them in acquiring much-needed supplies due to the scarcity of air freight capacity. As one of the few global logistics players in the Islands and one with a geographic footprint as wide as ours, we are glad to be able to play a part in delivering the medical equipment and living up to our purpose of ‘Connecting People, Improving Lives,” said Kelvin Leung, CEO, DHL Global Forwarding Asia Pacific.

 

More than ever before, the criticality of logistics networks have been demonstrated in the battle to get much needed supplies to countries that need it the most. Since the start of the year, DHL Global Forwarding tapped on its network of life science and healthcare facilities, temperature-controlled solutions and customs clearance expertise to fly more than 1.3 million COVID-19 test kits from South Korea to Brazil, Ecuador, India, Lithuania, Poland, Russia and Saudi Arabia. The freight forwarder also launched a dedicated 100-ton weekly air freight service for organizations and governments shipping health and medical-related items and other goods from China to Middle East and Africa.

 

Note to editors:

Vaccine logistics for Covid-19 will pose challenges along the supply chain that must be jointly addressed by governments, NGOs, pharmaceutical companies, and logistics players urgently. Find out what lessons Covid-19 has taught on securing stable supply chains for future emergencies and the complexities in distributing the vaccine across the globe.


DHL – The logistics company for the world

DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With about 380,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as “The logistics company for the world”.

DHL is part of Deutsche Post DHL Group. The Group generated revenues of more than 63 billion euros in 2019. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. Deutsche Post DHL Group aims to achieve zero-emissions logistics by 2050.

Continue Reading

News

Virtual event TECHFEST VIETNAM 2020 – the determination of Vietnamese government to connect resources, acting as a springboard for innovative startups

gbafNews28

HA NOI, VIETNAM – Media OutReach – 26 November 2020 – The national festival for innovative startups, TECHFEST VIETNAM 2020, will be held from November 26-29 in Ha Noi.

[View Image]

This is the largest annual virtual event organized by the Ministry of Science and Technology of Vietnam (MOST) to cooperate with international partners to develop and promote science, technology, and innovation in Vietnam in particular and South East Asia in general.

Taking place amid the global disruption caused by the COVID-19 pandemic, TECHFEST shows an emerging nation eager to display the dynamism of the Vietnamese start-up ecosystem among investors/investment funds, enterprises, and experts worldwide via virtual events on techfest.vn.

Themed ‘Respond – Transform — Break through’, TECHFEST VIETNAM 2020 will be structured into 12 technology villages: (1) Medical Technology (2) Agricultural Technology (3) Educational Technology (4) Tourism and F&B Technology (5) Frontier Technology (6) Financial Technology (7) Smart Cities (8) Social Impact (9) Student Start-ups (10) Local Start-ups (11) Community (12) International village, with 250 potential start-ups booths, attracting nearly 200 investors, 150 corporations, enterprises and business accelerators virtually and physically.

Notably, social impacts on innovative start-up solutions and business models will be presented in the Social Impact Technology Village by UNDP Vietnam and WWF Vietnam. MOST will work with partners to organize a High-Level Policy Dialogue, in which Prime Minister Nguyen Xuan Phuc will hold a discussion with the innovative start-up community on solving difficulties in conducting business and creating a favourable environment for start-up to grow.

After six years of implementation, local TECHFEST events have been organized in 15 provinces; the national TECHFEST VIETNAM has attracted around 30,000 people, of which international experts and investors accounted for more than 40%. In 2019, TECHFEST was held on an international scale for the first time in three developed startup-up ecosystems: the United States, South Korea, and Singapore, facilitating 20 prominent Vietnamese start-ups to access the global market and connecting over 100 international investors to the Vietnamese start-up ecosystem. In sum, there are about 500 local and international investors with approximately 700 investment with total value up to US$20 million. Among the startups connected, Abivin, the champion of TECHFEST 2019, was chosen to participate in the competition and then won in the international arena called Startup World Cup 2018.

Continue Reading

News

ESR inks multi-lease agreement with Mitsubishi Fuso Truck and Bus Corporation at ESR Yokohama Sachiura park clearing strategic Higashi Ogishima site for imminent development

gbafNews28

Transaction results in accelerated leasing at ESR Yokohama Sachiura DC1 and development commencement of ESR Higashi Ogishima DC1

 

TOKYO, JAPAN/HONG KONG SAR – Media OutReach – 26 November 2020 – ESR Cayman Limited (“ESR” or the “Group”; SEHK Stock Code: 1821), the largest APAC focused logistics real estate platform, and Mitsubishi Fuso Truck and Bus Corporation (“MFTBC” or “Mitsubishi Fuso”) have worked closely on a sweeping reorganisation of logistics operations in Kanagawa prefecture, Japan. The landmark transaction has resulted in 2 new lease agreements between ESR and MFTBC and material amendment of a third one. It involves ESR’s 2 leading park projects under development in Tokyo with a combined total build-out area of circa 900,000 sqm and expected completion value in excess of US$3.0 billion.

 

Higashi Ogishima: the parties have agreed to relocate MFTBC’s 1,200-truck domestic parking operation away from its historical site in Higashi Ogishima which ESR has controlled since 2016. The 8 Ha site being vacated will now develop as the first phase of ESR Higashi Ogishima park. Construction of the 310,000 sqm Higashi Ogishima DC 1 will commence next month for planned delivery in December 2022.

 

Featuring the first ever 9-storey warehouse design in Japan as well as advanced sustainability solutions ESR Higashi Ogishima park will set a new benchmark for distribution centre design where optimal integration into the urban fabric and lower environmental impact are achieved without sacrificing building functionality and high-throughput. E-commerce and 3PLs choosing to operate at ESR Higashi Ogishima will enjoy close proximity to Haneda Airport and Tokyo 23 wards as well as a supportive ecosystem with co-location of ancillary services including children’s day-care facilities of ESR partner BARNKLÜBB.

 

ESR Yokohama Sachiura Park: MFTBC has chosen to continue the domestic distribution of its complete vehicles at ESR’s other distribution park in the greater Tokyo area, ESR Yokohama Sachiura. More specifically, MFTBC will operate from the 15 Ha expansion area earmarked by ESR for bespoke logistics space requirements. In addition, Mitsubishi FUSO has reserved 4 Ha of adjacent space to allow the potential future consolidation of other logistics activities into a large built-to-suit facility to be developed by ESR.

 

In a further endorsement of the ESR Yokohama Sachiura park, MFTBC has also elected to locate additional operations in building DC1. As a result, ESR Yokohama Sachiura park which is halfway into development will achieve 38% pre-completion occupancy across its circa 350,000 sqm net rentable area.

Stuart Gibson, Co-founder and Co-CEO of ESR, commented: “This transaction is especially gratifying as it showcases several key capability differentiators of the ESR platform. Evidently it allows our most prized land holding to develop timely into ESR’s most advanced product to date. It also helps us cement our relationship with MFTBC who has been a fantastic partner and who is equally interested in bringing innovative solutions to our common set of third-party logistics clients with their superior product line of commercial vehicles.”

 

Arne Barden, Head of Supply Chain Management MFTBC, equally welcomed the transaction observing that “ESR’s Yokohama Sachiura site is strategically located in Kanagawa Prefecture and will invigorate the continuous improvements we implement in our operations” and expressed interest in “further collaborating with ESR on sustainability initiatives aimed at urban logistics”.

 

Stefan Rödler, Head of Asia-Pacific Real Estate at Mitsubishi Fuso’s parent company Daimler AG, who steered the local teams through the year-long negotiation concluded: “ESR has proven a reliable and creative partner and we look forward to expanding collaboration across other geographies to provide other Daimler business units with the same service level.”

 

Reflecting on industry trends Mr. Gibson remarked that this transaction vindicates ESR’s longstanding choice of targeting larger and more capital-intensive brownfield sites — including the ones where patient and strategic asset management work is required — in the pursuit of the large multi-tenanted buildings and parks favoured by occupiers and that “the ability of all the ESR teams to bend functional lines to come as one on complex transactions should serve ESR and its investors well in an increasingly competitive market.”  

 

Expanding on Mr. Gibson’s comment, Pierre-Alexandre Humblot, ESR Managing Director Fund Management and Capital, emphasised the central role played by the 2 development funds involved – RJLF2 and RJLF3 – and their investor representatives: “Managing a plain-vanilla development on behalf of 3rd-party capital is difficult enough. Here we had brownfield sites, criss-crossed ownership by vehicles with different mandates and a large corporate tenant suitably expecting their evolving occupancy requirements to be the leading consideration. Our LPs displayed great agility to focus on the bigger picture in a sign that 3rd-party capital is eager and capable of undertaking the more advanced transactions provided they are afforded the most complete insights into the developer thought process.”

 

The related sale of Higashi Ogishima Phase 1 accelerates RJLF2 divestment while allowing RJLF3 to complete its circa US$600 million equity deployment just 18 months into its investment period.

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News27 mins ago

7-Eleven teams up with 8 popular Sanrio characters to launch a Mini Pouch Collectible Programme “Little Baubles of Joy”

HONG KONG SAR – Media OutReach – 26 November 2020 – The countdown to Christmas has well and truly begun! So, let’s get into...

gbafNews28 gbafNews28
News27 mins ago

Sunlight Real Estate Investment Trust Issued HK$300 Million Five-year Medium Term Notes

HONG KONG SAR – Media OutReach – 26 November 2020 – Henderson Sunlight Asset Management Limited (the “Manager“) is pleased to announce that...

gbafNews28 gbafNews28
News27 mins ago

ChickP, the First in the World to Launch the Groundbreaking 90% Chickpea Isolate, Successfully Patents Its Brainchild in Israel

Investor Growthwell Group, a Local, Temasek-backed Plant-based Meat Manufacturer, Is Helping the Company Apply for a Patent in Singapore  ...

gbafNews28 gbafNews28
News27 mins ago

ESR inks multi-lease agreement with Mitsubishi Fuso Truck and Bus Corporation at ESR Yokohama Sachiura park clearing strategic Higashi Ogishima site for imminent development

Transaction results in accelerated leasing at ESR Yokohama Sachiura DC1 and development commencement of ESR Higashi Ogishima DC1   TOKYO,...

gbafNews28 gbafNews28
News27 mins ago

Virtual event TECHFEST VIETNAM 2020 – the determination of Vietnamese government to connect resources, acting as a springboard for innovative startups

HA NOI, VIETNAM – Media OutReach – 26 November 2020 – The national festival for innovative startups, TECHFEST VIETNAM 2020,...

gbafNews28 gbafNews28
News27 mins ago

DHL sends healthcare supplies for World Health Organization to the Pacific Islands

Tourism-dependent islands badly impacted by more than 90% decline in passenger flights Supplementary COVID-19 supplies moved through Singapore and Fiji...

gbafNews28 gbafNews28
News27 mins ago

Ericsson ConsumerLab Report: Digital Technologies to Augment Singapore’s Transportation Infrastructure

43 percent of Savvy Commuters feel that they receive plenty of mental space when commuting 40% of Singaporeans feel that...

gbafNews28 gbafNews28
News27 mins ago

Communications Association of Hong Kong Supports The New Initiatives on Telecommunications Industry in The Chief Executive’s 2020 Policy Address

New initiatives will be beneficial to the long-term development of innovation and technology and the implementation of the Smart City...

gbafNews28 gbafNews28
News27 mins ago

Senoko Energy Rewards Customers With Delights To Illuminate Holiday Season

Senoko Energy introduces thoughtfully curated offers & special giveaways to reward customers and brighten up the festive season   SINGAPORE...

gbafNews28 gbafNews28
News27 mins ago

Lead8 Design for Newly Unveiled ‘11 SKIES’ in Hong Kong

Hong Kong’s $20 Billion Mixed-use Destination at SKYCITY   HONG KONG SAR – Media OutReach – 25 November 2020 – Lead8, the...